Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.375 USD | -1.91% |
|
-3.95% | -35.30% |
03/06 | UniQure Shares Rise After US FDA Grants Regenerative Medicine Advanced Designation for Huntington's Treatment | MT |
03/06 | UniQure's AMT-130 Gets FDA RMAT Designation in Huntington's Disease | DJ |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-35.30% | 217M | B- | ||
+16.40% | 122B | B+ | ||
+21.46% | 116B | B+ | ||
+22.18% | 27.03B | B | ||
-21.91% | 20.36B | B+ | ||
-16.89% | 16.43B | A- | ||
-18.50% | 15.91B | B | ||
-44.74% | 15.6B | A- | ||
+61.88% | 14.94B | C+ | ||
+2.88% | 13.59B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- QURE Stock
- Ratings uniQure N.V.